Fulcrum Therapeutics (FULC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FULC Fulcrum Therapeutics

Watchlist

4.755
+0.205+4.51%

Trading Dec 26 15:27 ET

256.48MMarket Cap-16.40P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Fulcrum Therapeutics Faces Genzyme Agreement Termination
TipRanksDec 23 16:57 ET
Express News | Fulcrum Therapeutics Inc - Sanofi to Terminate Collaboration and License Agreement With Fulcrum
ReutersDec 23 16:33 ET
Fulcrum Therapeutics Rumor Highlighted in Betaville Alert
TipRanksDec 23 13:55 ET
Express News | Shares Of Fulcrum Therapeutics See Volume; Traders Circulating Co. Mentioned By M&A Blog
BenzingaDec 23 13:50 ET
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Yahoo FinanceDec 19 12:07 ET
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%
Simply Wall StDec 15 07:23 ET

Comments

Iwill TradeScared

Sep 26 19:48

$Fulcrum Therapeutics (FULC.US)$ 👀lot of meat on forcast but pattern is behaving like walking drunk man….

Jaguar8

Sep 12 07:11

NEWS

$Fulcrum Therapeutics (FULC.US)$
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...

Trytosaveabit

Jul 31 12:53

Up is the way!

$Fulcrum Therapeutics (FULC.US)$ Low volume indeed! But low or high volume, all that matters is that it’s moving up nicely

Trytosaveabit

Jul 31 06:11

Talk about a under estimated or a killer unexpected operating income! Hehehe!

$Fulcrum Therapeutics (FULC.US)$ Fulcrum Therapeutics Q2 Operating Income USD 52.492 Million Vs. IBES Estimate USD 361.4 Thousand! Hope the rest of the earnings looks like this? hehehe

Trytosaveabit

May 23 08:23

Note the timeline

$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.

Heat List

Overall

No Data